• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Ask the Expert / Mobic vs. Vioxx

Mobic vs. Vioxx

April 15, 2007 By Arthritis Center

Question

I have taken vioxx the past couple of years with great results. I am now being given the opportunity to replace Vioxx with Mobic. With the recent announcement of Bectra(sp) also under attack, is it ‘smart’ to proceed down the Cox2-road with Mobic or should I try something else?

Answer

Mobic is technically not a full fledged COX-2 agent. It is not as selective for the COX-2 enzyme as Celebrex, Vioxx and Bextra and thus the FDA did not give it a COX-2 labelling. But your question is a good one nonetheless.

If you have signficant GI problems such as a history of stomach ulcer or GI bleed, or if you are taking anticoagulants (coumadin) you may still need or want to be on a COX-2 agent because they are safer on the stomach. However, if you cardiovascular problems you may wish to avoid the COX-2 agents even the near COX-2 drugs such as Mobic. If you are on these COX-2 drugs, your doctor may want you to take low dose aspirin to protect against heart attacks and strokes. Taking an older NSAID together with a medication to protet your stomach such as Prilosec may also make sense.

You also need to be aware that the cardiovascular risk of Bextra, Celebrex or Mobic has not been proven and is only theoretical at the present time.

The risks of the COX-2 drugs and the alternative older NSAIDs (naproxen, ibuprofen, etc) need to be assessed for the individual patient. You need to discuss your situation with your doctor. It can be a complex decision.

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Primary Sidebar

Ask The Expert Topics

  • Alternative Therapies
  • Ankylosing Spondylitis
  • Associated With Other Illnesses
  • Bursitis and Tendinitis
  • Corticosteroids
  • Diet and Exercise
  • Disease Modifying Antirheumatic Drugs (DMARDs)
  • Enteropathic Arthritis
  • Fibromyalgia
  • General Arthritis
  • Gout, Pseudogout, Other
  • Infectious Arthritis
  • Myositis
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Osteoarthritis
  • Osteonecrosis
  • Osteoporosis
  • Polymyalgia Rheumatica
  • Psoriatic Arthritis
  • Reactive Arthritis
  • Regional Pain: Back and Neck
  • Rehabilitation
  • Rheumatoid Arthritis
  • Surgical Therapy
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis
  • Vasculitis
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy